STAT Plus: This biotech just bought three failed drugs. Here’s why
ADOBE
CODA wants to use the drug candidates to activate the gene therapies it’s working on for a form of epilepsy and a neurological condition that causes pain.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario